{"id":7290,"date":"2025-11-13T15:23:15","date_gmt":"2025-11-13T15:23:15","guid":{"rendered":"https:\/\/oncopeptides.com\/newsroom\/news\/video-nu-tillganglig-oncopeptides-anordnade-till-capital-markets-update-13-november\/"},"modified":"2025-11-13T15:23:15","modified_gmt":"2025-11-13T15:23:15","slug":"video-nu-tillganglig-oncopeptides-anordnade-till-capital-markets-update-13-november","status":"publish","type":"news","link":"https:\/\/oncopeptides.com\/sv\/nyheter\/video-nu-tillganglig-oncopeptides-anordnade-till-capital-markets-update-13-november\/","title":{"rendered":"VIDEO NU TILLG\u00c4NGLIG: Oncopeptides anordnade till Capital Markets Update 13 november"},"content":{"rendered":"<p class=\"preamble\">Oncopeptides AB h\u00f6ll den 13 november 2025 en Capital Markets Update, som s\u00e4ndes live och spelades in fr\u00e5n Inderes studio i Stockholm.<\/p>\n<p>Evenemanget gav aktie\u00e4gare och investerare en djupare inblick i bolagets strategiska riktning, tillv\u00e4xtplaner och den v\u00e4xande rollen i behandlingslandskapet f\u00f6r multipelt myelom.<\/p>\n<p>Programmet inneh\u00e5ller presentationer och diskussioner med <strong>ledande internationella experter<\/strong> fr\u00e5n Europa, Japan och USA, som ger kliniska, vetenskapliga och marknadsm\u00e4ssiga perspektiv. Bland talarna finns: <\/p>\n<ul>\n<li><strong>Prof. Dr. Sebastian Theurich<\/strong>, LMU University Hospital M\u00fcnchen<\/li>\n<li><strong>Dr. Mar\u00eda-Victoria Mateos<\/strong>, University of Salamanca<\/li>\n<li><strong>Dr. Claudio Cerchione<\/strong>, IRST IRCCS, Italien<\/li>\n<li><strong>Prof. Dr. med. Klaus Fenchel<\/strong>, Tyskland<\/li>\n<li><strong>Prof. Shinsuke Iida<\/strong>, Nagoya City University, Japan<\/li>\n<li><strong>Prof. Paul G. Richardson<\/strong>, Dana-Farber Cancer Institute \/ Harvard Medical School, USA<\/li>\n<\/ul>\n<p>Dessutom delade <strong>Dr. Bj\u00f6rn Odlander,<\/strong> grundare av HealthCap, och Oncopeptides <strong>vd Sofia Heigis<\/strong> sina perspektiv p\u00e5 bolagets aff\u00e4rsutsikter och investeringscase.<\/p>\n<p>&nbsp;<\/p>\n<h2>Ladda ned power point-bilderna fr\u00e5n evenemanget:<\/h2>\n<p><a class=\"btn btn-green\" href=\"https:\/\/oncopeptides.com\/app\/uploads\/2025\/12\/oncopeptides_cmu-nov13-2025.pdf\" target=\"_blank\" rel=\"noopener\">Oncopeptides Slides CMU 13 november, 2025<\/a><\/p>\n<p>&nbsp;<\/p>\n<h2>Se lives\u00e4ndningen nedan:<\/h2>\n<p>Evenemanget h\u00f6lls p\u00e5 engelska och streamades live. En inspelningen finns tillg\u00e4nglig on-demand h\u00e4r nedan. F\u00f6r att se den fullst\u00e4ndiga agendan, v\u00e4nligen skrolla l\u00e4ngre ner. Det g\u00e5r ocks\u00e5 att v\u00e4lja olika kapitel av dagen, uppbyggda efter agendan.  <\/p>\n<p><iframe src=\"https:\/\/player.vimeo.com\/video\/1136990331?dnt=1&amp;app_id=122963\" width=\"800\" height=\"450\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture; clipboard-write; encrypted-media; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\"><\/iframe><\/p>\n<p>&nbsp;<\/p>\n<h2 class=\"mfn-wp-retain\">Fullst\u00e4ndig agenda<\/h2>\n<p class=\"mfn-wp-retain\"><em>Evenemanget kommer att h\u00e5llas p\u00e5 engelska. Alla tider i CET. Dagordningen kan komma att \u00e4ndras.  <\/em><\/p>\n<p class=\"mfn-wp-retain\"><strong>09.00 \u2013 09.03 | Welcome<\/strong><br \/>\nSpeaker: <strong>David <\/strong><em><strong>Augustsson<\/strong><\/em><strong>,<\/strong> Director of IR, Oncopeptides.<\/p>\n<p class=\"mfn-wp-retain\"><strong>09.03-09.20 | Bringing Hope through Science<\/strong><br \/>\nSpeaker: <strong>Sofia Heigis<\/strong>, CEO, Oncopeptides.<\/p>\n<p class=\"mfn-wp-retain\"><strong>09.20-09.30 | Owner\u2019s perspective<\/strong><br \/>\nSpeaker: <strong>Dr.<\/strong> <strong>Bj\u00f6rn Odlander,<\/strong> founder and managing partner, HealthCap.<\/p>\n<p class=\"mfn-wp-retain\"><strong>09.30-9.55 | Keynote 1: Multiple myeloma and the unmet medical need<\/strong><br \/>\nSpeaker: <strong>Prof. Dr. Sebastian Theurich.<\/strong><br \/>\nDescription: An introduction to multiple myeloma and the treatment landscape, emphasizing the need for new treatments in the 4L+ stage.<\/p>\n<p class=\"mfn-wp-retain\"><strong>9.55-10.00 | From Need to Treatment \u2013 A Clinician\u2019s Reflection<\/strong><br \/>\nSpeaker: <strong>Dr.<\/strong> <strong>Mar\u00eda\u2011Victoria Mateos.<\/strong><br \/>\nDescription: Dr. Mateos shares her perspective on the evolving treatment landscape and the clinical relevance of Pepaxti in addressing unmet needs in relapsed and refractory multiple myeloma.<\/p>\n<p class=\"mfn-wp-retain\"><strong>10.00-10.25 | Conversation: Relapsed, refractory multiple myeloma \u2013 clinical experience with Pepaxti<\/strong><br \/>\nSpeakers: <strong>Dr.<\/strong> <strong>Claudio Cerchione<\/strong>, <strong>Prof. Dr. med.<\/strong> <strong>Klaus Fenchel<\/strong>.<br \/>\nDescription: A conversation on the European multiple myeloma landscape and the treatment challenges facing today\u00b4s healthcare practitioners.<\/p>\n<p class=\"mfn-wp-retain\"><strong>10.25-10.35 | BREAK<\/strong><\/p>\n<p class=\"mfn-wp-retain\"><strong>10.35-10.45 | Keynote 2: The Japanese Multiple Myeloma landscape<\/strong><br \/>\nSpeaker: <strong>Prof. Shinsuke Iida.<\/strong><\/p>\n<p class=\"mfn-wp-retain\"><strong>10.45-10.55 | Keynote 3: The potential of the PDC platform in the U.S.<\/strong><br \/>\nSpeaker: <strong>Prof. Paul Richardson.<\/strong><\/p>\n<p class=\"mfn-wp-retain\"><strong>10.55-11.30 | Oncopeptides as an investment case \u2013 where do we go from here?<\/strong><br \/>\nSpeaker: <strong>Sofia Heigis,<\/strong> CEO, Oncopeptides.<\/p>\n<p class=\"mfn-wp-retain\"><strong>11.30-11.45 | Questions and Answers from investors<\/strong><br \/>\nAll in-person participants.<\/p>\n<p class=\"mfn-wp-retain\"><strong>11.45-11.50 | Closing remarks<\/strong><br \/>\nSpeaker: <strong>Sofia Heigis,<\/strong> CEO, Oncopeptides.<\/p>\n","protected":false},"featured_media":7289,"template":"","meta":{"_acf_changed":false},"news_categories":[365],"protected-content":[],"class_list":["post-7290","news","type-news","status-publish","has-post-thumbnail","hentry","news_categories-investerare"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news\/7290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media\/7289"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=7290"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=7290"},{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=7290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}